Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Subjects With Multiple Myeloma

NCT04108195 is registered in ClinicalTrials.gov with Janssen Research & Development, LLC as lead sponsor.

NCT NCT04108195
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04108195 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Subjects With Multiple Myeloma
Lead sponsor
Janssen Research & Development, LLC
Phase
Phase 1
Overall status
Active, not recruiting
Start date
February 21, 2020
Completion date
December 31, 2027
Enrollment
290 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma